Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

200 - Introduction of a novel cancer cell targeted fusion protein: DT386-BR2


05 Mar 2018


Poster display


Ali Jahanian-Najafabadi


Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047


A. Jahanian-Najafabadi1, F. Shafiee1, M. Rabbani2

Author affiliations

  • 1 Department Of Pharmaceutical Biotechnology, Isfahan University of Medical Sciences, 8174673461 - Isfahan/IR
  • 2 Department Of Pharmacology And Toxicology, Isfahan University of Medical Sciences, 8174673461 - Isfahan/IR


Abstract 200

Due to the adverse side effects of current cancer chemotherapeutics development of targeted anti-cancer medications is under intensive focus. In the present study a fusion protein consisting of the catalytic and translocation domains of diphtheria toxin fused to BR2, a cancer specific cell penetrating peptide, was produced as a new targeted anti-cancer agent and its cytotoxic effects on various cell lines including MCF-7 and HeLa (as cancerous), and HEK293 and HUVEC (as normal) cell lines was evaluated.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings